Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model

Hyeon Cheol Cho; Bo Hwan Kim; Kyunghoon Kim; Ju Youn Park; Jae Ho Chang; Soo Ki Kim

doi:10.1016/j.intimp.2008.05.010

Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model

Hyeon Cheol Cho, Bo Hwan Kim, Kyunghoon Kim, Ju Youn Park, Jae Ho Chang, Soo Ki Kim

Microbiology

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

While CpG oligodeoxynucleotides (ODN) are excellent candidates for cancer immunotherapeutics, the numbers of usable CpG ODNs are limited in current clinical settings. To resolve this, we investigated whether novel CpG ODN (KSK-CpG) would be an effective immunotherapeutic in a murine tumor model by affecting in vivo and in vitro parameters, such as survival span, the number of tumor nodules, natural killer (NK) cell and cytotoxic T lymphocyte (CTL) activity and interleukin (IL)-6 or IL-12 cytokine release in splenocytes. We found that KSK-CpG was effective in the murine cancer model by way of prolonging survival span, reducing the number of tumor nodules, augmenting NK cell and CTL cytotoxicity, as well as evoking IL-6 and IL-12 cytokine release in splenocytes. Collectively, these data demonstrate that KSK-CpG is active against the highly malignant B16BL6 and EL4 tumor mouse model via innate immune augmentation. Crown

Original language	English
Pages (from-to)	1401-1407
Number of pages	7
Journal	International Immunopharmacology
Volume	8
Issue number	10
DOIs	https://doi.org/10.1016/j.intimp.2008.05.010
Publication status	Published - 2008 Oct

Bibliographical note

Funding Information:
This study was supported by a grant from National Cancer Control R&D Program 2002 and a grant (A050485) of the Korea Health 21 R&D Project Ministry of Health & Welfare, and by a grant (06132KFDA395) from Korea Food & Drug Administration in 2006, Republic of Korea.

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Immunology
Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.intimp.2008.05.010

Cite this

@article{574ef20faa51497cb306eef6c346fbb3,

title = "Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model",

abstract = "While CpG oligodeoxynucleotides (ODN) are excellent candidates for cancer immunotherapeutics, the numbers of usable CpG ODNs are limited in current clinical settings. To resolve this, we investigated whether novel CpG ODN (KSK-CpG) would be an effective immunotherapeutic in a murine tumor model by affecting in vivo and in vitro parameters, such as survival span, the number of tumor nodules, natural killer (NK) cell and cytotoxic T lymphocyte (CTL) activity and interleukin (IL)-6 or IL-12 cytokine release in splenocytes. We found that KSK-CpG was effective in the murine cancer model by way of prolonging survival span, reducing the number of tumor nodules, augmenting NK cell and CTL cytotoxicity, as well as evoking IL-6 and IL-12 cytokine release in splenocytes. Collectively, these data demonstrate that KSK-CpG is active against the highly malignant B16BL6 and EL4 tumor mouse model via innate immune augmentation. Crown",

author = "Cho, {Hyeon Cheol} and Kim, {Bo Hwan} and Kyunghoon Kim and Park, {Ju Youn} and Chang, {Jae Ho} and Kim, {Soo Ki}",

note = "Funding Information: This study was supported by a grant from National Cancer Control R&D Program 2002 and a grant (A050485) of the Korea Health 21 R&D Project Ministry of Health & Welfare, and by a grant (06132KFDA395) from Korea Food & Drug Administration in 2006, Republic of Korea.",

year = "2008",

month = oct,

doi = "10.1016/j.intimp.2008.05.010",

language = "English",

volume = "8",

pages = "1401--1407",

journal = "International Immunopharmacology",

issn = "1567-5769",

publisher = "Elsevier",

number = "10",

}

TY - JOUR

T1 - Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model

AU - Cho, Hyeon Cheol

AU - Kim, Bo Hwan

AU - Kim, Kyunghoon

AU - Park, Ju Youn

AU - Chang, Jae Ho

AU - Kim, Soo Ki

N1 - Funding Information: This study was supported by a grant from National Cancer Control R&D Program 2002 and a grant (A050485) of the Korea Health 21 R&D Project Ministry of Health & Welfare, and by a grant (06132KFDA395) from Korea Food & Drug Administration in 2006, Republic of Korea.

PY - 2008/10

Y1 - 2008/10

N2 - While CpG oligodeoxynucleotides (ODN) are excellent candidates for cancer immunotherapeutics, the numbers of usable CpG ODNs are limited in current clinical settings. To resolve this, we investigated whether novel CpG ODN (KSK-CpG) would be an effective immunotherapeutic in a murine tumor model by affecting in vivo and in vitro parameters, such as survival span, the number of tumor nodules, natural killer (NK) cell and cytotoxic T lymphocyte (CTL) activity and interleukin (IL)-6 or IL-12 cytokine release in splenocytes. We found that KSK-CpG was effective in the murine cancer model by way of prolonging survival span, reducing the number of tumor nodules, augmenting NK cell and CTL cytotoxicity, as well as evoking IL-6 and IL-12 cytokine release in splenocytes. Collectively, these data demonstrate that KSK-CpG is active against the highly malignant B16BL6 and EL4 tumor mouse model via innate immune augmentation. Crown

AB - While CpG oligodeoxynucleotides (ODN) are excellent candidates for cancer immunotherapeutics, the numbers of usable CpG ODNs are limited in current clinical settings. To resolve this, we investigated whether novel CpG ODN (KSK-CpG) would be an effective immunotherapeutic in a murine tumor model by affecting in vivo and in vitro parameters, such as survival span, the number of tumor nodules, natural killer (NK) cell and cytotoxic T lymphocyte (CTL) activity and interleukin (IL)-6 or IL-12 cytokine release in splenocytes. We found that KSK-CpG was effective in the murine cancer model by way of prolonging survival span, reducing the number of tumor nodules, augmenting NK cell and CTL cytotoxicity, as well as evoking IL-6 and IL-12 cytokine release in splenocytes. Collectively, these data demonstrate that KSK-CpG is active against the highly malignant B16BL6 and EL4 tumor mouse model via innate immune augmentation. Crown

UR - http://www.scopus.com/inward/record.url?scp=50949102674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50949102674&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2008.05.010

DO - 10.1016/j.intimp.2008.05.010

M3 - Article

C2 - 18687302

AN - SCOPUS:50949102674

SN - 1567-5769

VL - 8

SP - 1401

EP - 1407

JO - International Immunopharmacology

JF - International Immunopharmacology

IS - 10

ER -

Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this